Skip to Main Content
DownloadHi-Res Photo

Noffar Bar, MD

Assistant Professor of Medicine (Hematology)

Contact Information

Noffar Bar, MD

Mailing Address

  • Hematology

    PO Box 208028

    New Haven, CT 06520-8028

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Bar is a member of the American Society of Clinical Oncology as well as the American Society of Hematology. She was awarded the Conquer Cancer Foundation’s Young Investigator Award for her work looking at the prevention of multiple myeloma.

Extensive Research Description

Dr. Bar is a member of the American Society of Clinical Oncology as well as the American Society of Hematology. She was awarded grant support through the Conquer Cancer Foundation’s Young Investigator Award for her work looking at the prevention of multiple myeloma. Dr. Bar's research interests focus on improving the care of patients with multiple myeloma and other plasma cell dyscrasias.

Coauthors

Selected Publications

  • Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart.Bar N, Parker TL, Dhodapkar MV. Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 3689-90. PMID: 26371139, DOI: 10.1200/JCO.2015.63.2224.

Clinical Trials

ConditionsStudy Title
Multiple MyelomaEffective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
KidneyA Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
Multiple MyelomaA Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Hodgkin's Lymphoma; Lymphoid Leukemia; Non-Hodgkin's LymphomaManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
Edit Profile